OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
January 15, 2021
The collaboration will focus on up to three types of lung and gastrointestinal cancers.
January 12, 2021
Under the terms of the agreement, operations will be initiated at Lonza’s Houston, TX Center of Excellence where Lonza will handle process development activities for late-clinical and commercial-scale GMP manufacturing of the cell therapy.
January 11, 2021
The draft guidance document offers developers of these treatments information regarding product development, preclinical testing, and clinical trial design.
January 05, 2021
Vendors are finding ways to address the increasingly complex analytical challenges in the biopharmaceutical industry to further biotherapeutic development.
January 04, 2021
Using rDNA technology to synthesize production of proteins and peptide hormones, the biotech startup has achieved synthetic production of insulin, potentially lowering insulin cost by 30%.
January 03, 2021
Biopharma looks to deliver on COVID-19 vaccines and other promising therapies.
Essential bio/pharma employees show hard work and dedication can pay off for patients.
Demand for specific advanced laboratory skills drives creates a positive employment market.
FDA approval rate speeds up despite COVID-19 complications.
The right partner can help companies overcome key formulation challenges for biologic drugs.